-

LifeScan Announces Transformational Partnership with i-SENS to Launch OneTouch® Continuous Glucose Monitoring System

Strengthens Leadership in Glucose Management Industry Through Expansion into CGM

MALVERN, Pa.--(BUSINESS WIRE)--LifeScan (“the “Company”), a world leader in glucose monitoring, today announced a transformational partnership with i-SENS, a global biosensor specialist, to launch a continuous glucose monitoring (“CGM”) system under the OneTouch® Vita brand. The Company and i-SENS expect to launch the CGM products in Germany, Ireland, Portugal, and Belgium by early 2027, with plans to expand into additional markets over time.

This announcement reflects LifeScan’s long-term commitment to bring new innovations to market to improve the quality of life for patients. With a shared focus on delivering meaningful solutions for people living with diabetes, this partnership will bring together LifeScan’s trusted OneTouch® brand and global distribution network with i-SENS advanced technology and manufacturing capacities. There are no changes across the rest of the OneTouch® portfolio in connection with this announcement.

“LifeScan has served the diabetes community for more than 40 years, and the addition of CGM is a significant milestone in the Company’s evolution,” said James Rushing, Chief Financial Officer, Office of the CEO, LifeScan. “This partnership allows us to bring a CGM solution to market under the OneTouch® Vita brand with the quality, reliability, and customer experience people expect from LifeScan. We are excited to begin this launch in Europe and continue to expand access in the years to come.”

“Launching a CGM product line has been a long-term goal for LifeScan and we are proud to take this important step toward realizing that ambition,” added Michael Hooks, Executive Chairman, Office of the CEO. “For years, we have seen the opportunity to incorporate CGM as a component of our offerings, and this partnership enables us to do so with a partner that shares our commitment to R&D excellence and product quality.”

About LifeScan

LifeScan is a global leader in glucose monitoring and digital health technology and has a vision to create a world without limits for people with diabetes. More than 20 million people and their caregivers around the world count on LifeScan's OneTouch® brand products to manage their diabetes. Together, LifeScan and OneTouch® improve the quality of life for people with diabetes with products and digital platforms defined by simplicity, accuracy, and trust. For more information, please visit LifeScan.com.

About i-SENS

i-SENS is a global in vitro diagnostics company that researches, develops, and produces products to support human health by leveraging advanced biosensor and electrochemical technologies. With many years of experience in technology development, along with patents and research capabilities, i-SENS continues to develop and launch pioneering, easy-to-use products. i-SENS blood glucose monitoring devices have been welcomed by customers in over 110 countries, including Korea, the United States, and across Europe, thanks to their intuitive design and accuracy.

Contacts

Media Contact – LifeScan
C Street Advisory Group
lifescan@thecstreet.com

LifeScan


Release Versions

Contacts

Media Contact – LifeScan
C Street Advisory Group
lifescan@thecstreet.com

More News From LifeScan

LifeScan Successfully Emerges from Financial Restructuring Process, Enters Next Chapter with Renewed Strength

MALVERN, Pa.--(BUSINESS WIRE)--LifeScan (the “Company”), a world leader in blood glucose monitoring, today announced its successful emergence from its Chapter 11 financial restructuring process following approval of its Plan of Reorganization on October 27, 2025. Through this process, the Company eliminated more than 75% of its debt, providing the financial flexibility needed to continue its leadership in the glucose management industry. In connection with emergence, LifeScan is now owned by a...

LifeScan Receives Court Approval of Plan of Reorganization, Positioned to Emerge as Leader in Glucose Management with Strengthened Financial Foundation

MALVERN, Pa.--(BUSINESS WIRE)--LifeScan Inc. (“LifeScan” or the “Company”), a world leader in blood glucose monitoring, today announced that its Chapter 11 Plan of Reorganization (the “Plan”) has been approved by the United States Bankruptcy Court for the Southern District of Texas (the “Court”). With this approval, the Company is positioned to emerge from its financial restructuring process by the end of this year. “Today’s approval marks a significant milestone in our financial restructuring...

LifeScan Reaches Milestone Transaction to Improve Financial Flexibility and Enable Future-Focused Investments

MALVERN, Pa.--(BUSINESS WIRE)--LifeScan, Inc. (“LifeScan” or the “Company”), a world leader in blood glucose monitoring, today announced that it has entered into a Restructuring Support Agreement (“RSA”) with its first- and second-lien lenders and current equity sponsor, Platinum Equity, that will transform its balance sheet and position the Company for a stronger and more profitable future. As contemplated in the RSA, LifeScan expects to reduce more than 75% of its debt, which will enable the...
Back to Newsroom